Publications by authors named "Marc Lang"

8Publications

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Authors:
Maximilien Murone Anne Vaslin Chessex Antoine Attinger Raghuveer Ramachandra Shankar J Shetty Girish Daginakatte Saumitra Sengupta Sivapriya Marappan Samiulla Dhodheri Stefania Rigotti Yogeshwar Bachhav Silvano Brienza Peter Traxler Marc Lang Michel Aguet Vincent Zoete Olivier Michielin Courtney Nicholas Faye M Johnson Murali Ramachandra Andres McAllister

Mol Cancer Ther 2016 10 20;15(10):2334-2343. Epub 2016 Jul 20.

Debiopharm International S.A., Lausanne, Switzerland.

View Article and Find Full Text PDF
October 2016

New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series.

Authors:
Frédéric Stauffer Pascal Furet Andreas Floersheimer Marc Lang

Bioorg Med Chem Lett 2012 Mar 28;22(5):1860-3. Epub 2012 Jan 28.

Novartis Institutes for BioMedical Research, Global Discovery Chemistry Oncology, Postfach, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2012

Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805.

Authors:
Fabienne Baffert Catherine H Régnier Alain De Pover Carole Pissot-Soldermann Gisele A Tavares Francesca Blasco Josef Brueggen Patrick Chène Peter Drueckes Dirk Erdmann Pascal Furet Marc Gerspacher Marc Lang David Ledieu Lynda Nolan Stephan Ruetz Joerg Trappe Eric Vangrevelinghe Markus Wartmann Lorenza Wyder Francesco Hofmann Thomas Radimerski

Mol Cancer Ther 2010 Jul 29;9(7):1945-55. Epub 2010 Jun 29.

Disease Area Oncology, Novartis Institutes for BioMedical Research, 4057 Basel, Switzerland.

View Article and Find Full Text PDF
July 2010

2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.

Authors:
Marc Gerspacher Pascal Furet Carole Pissot-Soldermann Christoph Gaul Philipp Holzer Eric Vangrevelinghe Marc Lang Dirk Erdmann Thomas Radimerski Catherine H Regnier Patrick Chene Alain De Pover Francesco Hofmann Fabienne Baffert Thomas Buhl Reiner Aichholz Francesca Blasco Ralf Endres Jörg Trappe Peter Drueckes

Bioorg Med Chem Lett 2010 Mar 21;20(5):1724-7. Epub 2010 Jan 21.

Novartis Institutes for BioMedical Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
March 2010

Entry into a new class of protein kinase inhibitors by pseudo ring design.

Authors:
Pascal Furet Giorgio Caravatti Vito Guagnano Marc Lang Thomas Meyer Joseph Schoepfer

Bioorg Med Chem Lett 2008 Feb 14;18(3):897-900. Epub 2008 Jan 14.

Novartis Institutes for BioMedical Research, WKL-136.P.12, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
February 2008

Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Authors:
Patricia Imbach Marc Lang Carlos García-Echeverría Vito Guagnano Maria Noorani Johannes Roesel Francis Bitsch Grety Rihs Pascal Furet

Bioorg Med Chem Lett 2007 Jan 24;17(2):358-62. Epub 2006 Oct 24.

Novartis Institutes for BioMedical Research, WKL-136.4.25, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
January 2007

Entry into a new class of potent proteasome inhibitors having high antiproliferative activity by structure-based design.

Authors:
Pascal Furet Patricia Imbach Maria Noorani Juergen Koeppler Kurt Laumen Marc Lang Vito Guagnano Peter Fuerst Johannes Roesel Johann Zimmermann Carlos García-Echeverría

J Med Chem 2004 Sep;47(20):4810-3

Novartis Pharma AG, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.

View Article and Find Full Text PDF
September 2004

Structure-based optimisation of 2-aminobenzylstatine derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.

Authors:
Pascal Furet Patricia Imbach Peter Fuerst Marc Lang Maria Noorani Johann Zimmermann Carlos García-Echeverría

Bioorg Med Chem Lett 2002 May;12(10):1331-4

Oncology Research, Novartis Pharma Inc., CH-4002, Basel, Switzerland.

View Article and Find Full Text PDF
May 2002